[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580910":3},{"organization":4,"armGroups":7,"interventions":58,"overallOfficials":106,"centralContacts":110,"locations":116,"responsibleParty":438,"collaborators":440,"id":443,"slug":71,"hasResults":444,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":71,"eligibilityCriteria":448,"healthyVolunteers":444,"sex":449,"minAge":450,"maxAge":71,"enrollmentInfo":451,"targetDuration":71,"studyType":454,"phases":455,"briefSummary":458,"conditions":459,"keywords":71,"overallStatus":119,"whyStopped":71,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":470},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,16,21,25,30,34,39,43,47,51],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)","EXPERIMENTAL","Participants receive escalating doses of intravenous (IV) raludotatug deruxtecan (R-DXd) in combination with carboplatin at Dose 1. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive raludotatug deruxtecan until disease progression or discontinuation.",[13,14,15],"Biological: Raludotatug Deruxtecan","Drug: Carboplatin","Drug: Rescue Medication",{"label":17,"type":10,"description":18,"interventionNames":19},"Cohort A-1 Arm 2 (R-DXd + Paclitaxel)","Participants receive escalating doses of IV R-DXd in combination with paclitaxel. Participants can receive up to a maximum of six 3-week cycles of paclitaxel (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.",[13,20,15],"Drug: Paclitaxel",{"label":22,"type":10,"description":23,"interventionNames":24},"Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)","Participants receive escalating doses of intravenous (IV) R-DXd in combination with carboplatin at Dose 2. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.",[13,14,15],{"label":26,"type":10,"description":27,"interventionNames":28},"Cohort B-1 (R-DXd + Bevacizumab)","Participants receive escalating doses of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.",[13,29,15],"Biological: Bevacizumab",{"label":31,"type":10,"description":32,"interventionNames":33},"Cohort B-2 (R-DXd RP2D + Bevacizumab)","Participants with platinum-resistant recurrent ovarian cancer (PRROC) receive recommended Phase 2 dose (RP2D) of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.",[13,29,15],{"label":35,"type":10,"description":36,"interventionNames":37},"Cohort C-1 (R-DXd + Pembrolizumab)","Participants receive escalating doses of IV R-DXd in combination with pembrolizumab. Participants can receive up to a maximum of thirty-five 3-week cycles of pembrolizumab (approximately 2 years) and will receive R-DXd until disease progression or discontinuation.",[13,15,38],"Biological: Pembrolizumab",{"label":40,"type":10,"description":41,"interventionNames":42},"Cohort D (R-DXd RP2D +\u002F- Bevacizumab)","Participants with platinum-sensitive recurrent ovarian cancer (PSROC) receive RP2D of IV R-DXd in combination with or without bevacizumab until disease progression or discontinuation.",[13,29,15],{"label":44,"type":10,"description":45,"interventionNames":46},"Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +\u002F- Bevacizumab)","Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of carboplatin with or without bevacizumab, until disease progression or discontinuation.",[13,14,29,15],{"label":48,"type":10,"description":49,"interventionNames":50},"Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +\u002F- Bevacizumab)","Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of paclitaxel with or without bevacizumab, until disease progression or discontinuation.",[13,20,29,15],{"label":52,"type":53,"description":54,"interventionNames":55},"Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +\u002F- Bevacizumab)","ACTIVE_COMPARATOR","Participants with PSROC will receive one of 3 regimens of investigator's choice of platinum-based doublet chemotherapy with or without bevacizumab. Platinum-based doublet chemotherapy will be administered for maximum of 8 cycles. Bevacizumab can be administered until disease progression or discontinuation.",[14,20,29,56,57],"Drug: Gemcitabine","Drug: Pegylated liposomal doxorubicin",[59,66,72,75,88,92,96,100],{"type":60,"name":61,"description":62,"armGroupLabels":63,"otherNames":64},"BIOLOGICAL","Raludotatug Deruxtecan","IV infusion on Day 1 of every 3-week cycle.",[9,17,22,44,48,26,31,35,40],[65],"MK-5909, R-DXd",{"type":67,"name":68,"description":69,"armGroupLabels":70,"otherNames":71},"DRUG","Carboplatin","IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.",[9,22,44,52],null,{"type":67,"name":73,"description":69,"armGroupLabels":74,"otherNames":71},"Paclitaxel",[17,48,52],{"type":60,"name":76,"description":62,"armGroupLabels":77,"otherNames":78},"Bevacizumab",[44,48,52,26,31,40],[79,80,81,82,83,84,85,86,87],"Includes, based on sourcing:","- Avastin®","- Alymsys®","- MVASI®","- Oyavas®","- Zirabev®","- Vegzelma®","- Aybintio®","- Breztri®",{"type":67,"name":89,"description":90,"armGroupLabels":91,"otherNames":71},"Rescue Medication","Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.",[9,17,22,44,48,26,31,35,40],{"type":60,"name":93,"description":94,"armGroupLabels":95,"otherNames":71},"Pembrolizumab","IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.",[35],{"type":67,"name":97,"description":98,"armGroupLabels":99,"otherNames":71},"Gemcitabine","IV injection on days 1 and 8 of each 3-week Cycle",[52],{"type":67,"name":101,"description":102,"armGroupLabels":103,"otherNames":104},"Pegylated liposomal doxorubicin","IV injection administered on Day 1 of each 4-week cycle",[52],[105],"PLD",[107],{"name":108,"affiliation":5,"role":109},"Medical Director","STUDY_DIRECTOR",[111],{"name":112,"role":113,"phone":114,"phoneExt":71,"email":115},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[117,135,148,161,173,186,199,209,222,235,249,261,273,285,300,308,320,333,344,353,362,374,389,402,413,426],{"facility":118,"status":119,"city":120,"state":121,"zip":122,"country":123,"countryCode":124,"cosmosGeoPoint":125,"geoPoint":130,"contacts":131},"Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)","RECRUITING","New Haven","Connecticut","06510","United States","US",{"type":126,"coordinates":127},"Point",[128,129],-72.92816,41.30815,{"lat":129,"lon":128},[132],{"name":133,"role":113,"phone":134,"phoneExt":71,"email":71},"Study Coordinator","203-785-2404",{"facility":136,"status":119,"city":137,"state":138,"zip":139,"country":123,"countryCode":124,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"The University of Louisville, James Graham Brown Cancer Center ( Site 0009)","Louisville","Kentucky","40202",{"type":126,"coordinates":141},[142,143],-85.75941,38.25424,{"lat":143,"lon":142},[146],{"name":133,"role":113,"phone":147,"phoneExt":71,"email":71},"502-562-3429",{"facility":149,"status":119,"city":150,"state":151,"zip":152,"country":123,"countryCode":124,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Dana-Farber Cancer Institute ( Site 0015)","Boston","Massachusetts","02215",{"type":126,"coordinates":154},[155,156],-71.05977,42.35843,{"lat":156,"lon":155},[159],{"name":133,"role":113,"phone":160,"phoneExt":71,"email":71},"877-338-7425",{"facility":162,"status":119,"city":163,"state":163,"zip":164,"country":123,"countryCode":124,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"Memorial Sloan Kettering Cancer Center ( Site 0003)","New York","10065",{"type":126,"coordinates":166},[167,168],-74.00597,40.71427,{"lat":168,"lon":167},[171],{"name":133,"role":113,"phone":172,"phoneExt":71,"email":71},"212-639-2000",{"facility":174,"status":119,"city":175,"state":176,"zip":177,"country":123,"countryCode":124,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"OU Health University of Oklahoma Medical Center ( Site 7000)","Oklahoma City","Oklahoma","73104",{"type":126,"coordinates":179},[180,181],-97.51643,35.46756,{"lat":181,"lon":180},[184],{"name":133,"role":113,"phone":185,"phoneExt":71,"email":71},"405-271-1112",{"facility":187,"status":119,"city":188,"state":189,"zip":190,"country":123,"countryCode":124,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"Texas Oncology - DFW ( Site 8000)","Fort Worth","Texas","76104",{"type":126,"coordinates":192},[193,194],-97.32085,32.72541,{"lat":194,"lon":193},[197],{"name":133,"role":113,"phone":198,"phoneExt":71,"email":71},"615-329-7430",{"facility":200,"status":201,"city":202,"state":189,"zip":203,"country":123,"countryCode":124,"cosmosGeoPoint":204,"geoPoint":208,"contacts":71},"Houston Methodist Hospital ( Site 0010)","COMPLETED","Houston","77030",{"type":126,"coordinates":205},[206,207],-95.36327,29.76328,{"lat":207,"lon":206},{"facility":210,"status":119,"city":211,"state":212,"zip":213,"country":123,"countryCode":124,"cosmosGeoPoint":214,"geoPoint":218,"contacts":219},"START Mountain Region ( Site 0008)","West Valley City","Utah","84119",{"type":126,"coordinates":215},[216,217],-112.00105,40.69161,{"lat":217,"lon":216},[220],{"name":133,"role":113,"phone":221,"phoneExt":71,"email":71},"801-907-4750",{"facility":223,"status":119,"city":224,"state":225,"zip":226,"country":123,"countryCode":124,"cosmosGeoPoint":227,"geoPoint":231,"contacts":232},"University of Virginia Health System ( Site 0011)","Charlottesville","Virginia","22908",{"type":126,"coordinates":228},[229,230],-78.47668,38.02931,{"lat":230,"lon":229},[233],{"name":133,"role":113,"phone":234,"phoneExt":71,"email":71},"434-924-9333",{"facility":236,"status":119,"city":237,"state":71,"zip":238,"country":239,"countryCode":240,"cosmosGeoPoint":241,"geoPoint":245,"contacts":246},"Rambam Health Care Campus ( Site 0202)","Haifa","3109601","Israel","IL",{"type":126,"coordinates":242},[243,244],34.99928,32.81303,{"lat":244,"lon":243},[247],{"name":133,"role":113,"phone":248,"phoneExt":71,"email":71},"972-4-7776234",{"facility":250,"status":119,"city":251,"state":71,"zip":252,"country":239,"countryCode":240,"cosmosGeoPoint":253,"geoPoint":257,"contacts":258},"Shaare Zedek Medical Center ( Site 0201)","Jerusalem","9103102",{"type":126,"coordinates":254},[255,256],35.21633,31.76904,{"lat":256,"lon":255},[259],{"name":133,"role":113,"phone":260,"phoneExt":71,"email":71},"+972-(0)2-6555424",{"facility":262,"status":119,"city":263,"state":71,"zip":264,"country":239,"countryCode":240,"cosmosGeoPoint":265,"geoPoint":269,"contacts":270},"Rabin Medical Center ( Site 0203)","Petah Tikva","4941492",{"type":126,"coordinates":266},[267,268],34.88747,32.08707,{"lat":268,"lon":267},[271],{"name":133,"role":113,"phone":272,"phoneExt":71,"email":71},"+97239378076",{"facility":274,"status":119,"city":275,"state":71,"zip":276,"country":239,"countryCode":240,"cosmosGeoPoint":277,"geoPoint":281,"contacts":282},"Sheba Medical Center ( Site 0200)","Ramat Gan","5265601",{"type":126,"coordinates":278},[279,280],34.81065,32.08227,{"lat":280,"lon":279},[283],{"name":133,"role":113,"phone":284,"phoneExt":71,"email":71},"972-3-5304498",{"facility":286,"status":119,"city":287,"state":288,"zip":289,"country":290,"countryCode":291,"cosmosGeoPoint":292,"geoPoint":296,"contacts":297},"Institut Català d'Oncologia - L'Hospitalet ( Site 0302)","L'Hospitalet de Llobregat","Barcelona","08908","Spain","ES",{"type":126,"coordinates":293},[294,295],2.10028,41.35967,{"lat":295,"lon":294},[298],{"name":133,"role":113,"phone":299,"phoneExt":71,"email":71},"+34932607744",{"facility":301,"status":119,"city":302,"state":303,"zip":304,"country":290,"countryCode":291,"cosmosGeoPoint":71,"geoPoint":71,"contacts":305},"HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)","Majadhonda","Madrid","28222",[306],{"name":133,"role":113,"phone":307,"phoneExt":71,"email":71},"+34 911917358",{"facility":309,"status":119,"city":303,"state":310,"zip":311,"country":290,"countryCode":291,"cosmosGeoPoint":312,"geoPoint":316,"contacts":317},"Clinica Universidad de Navarra ( Site 0301)","Madrid, Comunidad de","28027",{"type":126,"coordinates":313},[314,315],-3.70256,40.4165,{"lat":315,"lon":314},[318],{"name":133,"role":113,"phone":319,"phoneExt":71,"email":71},"+349135319207513",{"facility":321,"status":119,"city":322,"state":323,"zip":324,"country":290,"countryCode":291,"cosmosGeoPoint":325,"geoPoint":329,"contacts":330},"Hospital General Universitario de Valencia ( Site 0305)","Valencia","Valenciana, Comunitat","46014",{"type":126,"coordinates":326},[327,328],-0.37966,39.47391,{"lat":328,"lon":327},[331],{"name":133,"role":113,"phone":332,"phoneExt":71,"email":71},"+34 963187527",{"facility":334,"status":119,"city":288,"state":71,"zip":335,"country":290,"countryCode":291,"cosmosGeoPoint":336,"geoPoint":340,"contacts":341},"Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)","08035",{"type":126,"coordinates":337},[338,339],2.15899,41.38879,{"lat":339,"lon":338},[342],{"name":133,"role":113,"phone":343,"phoneExt":71,"email":71},"+349325434528607",{"facility":345,"status":119,"city":303,"state":71,"zip":346,"country":290,"countryCode":291,"cosmosGeoPoint":347,"geoPoint":349,"contacts":350},"Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)","28040",{"type":126,"coordinates":348},[314,315],{"lat":315,"lon":314},[351],{"name":133,"role":113,"phone":352,"phoneExt":71,"email":71},"34915504800 x2805",{"facility":354,"status":119,"city":303,"state":71,"zip":355,"country":290,"countryCode":291,"cosmosGeoPoint":356,"geoPoint":358,"contacts":359},"Hospital Universitario 12 de Octubre ( Site 0304)","28041",{"type":126,"coordinates":357},[314,315],{"lat":315,"lon":314},[360],{"name":133,"role":113,"phone":361,"phoneExt":71,"email":71},"+34913908626",{"facility":363,"status":119,"city":364,"state":71,"zip":365,"country":290,"countryCode":291,"cosmosGeoPoint":366,"geoPoint":370,"contacts":371},"Hospital Universitario Virgen de la Victoria ( Site 0306)","Málaga","29010",{"type":126,"coordinates":367},[368,369],-4.42034,36.72016,{"lat":369,"lon":368},[372],{"name":133,"role":113,"phone":373,"phoneExt":71,"email":71},"+34951032508",{"facility":375,"status":119,"city":376,"state":377,"zip":378,"country":379,"countryCode":380,"cosmosGeoPoint":381,"geoPoint":385,"contacts":386},"University Hospitals Sussex NHS Foundation Trust ( Site 0404)","Brighton","East Sussex","BN2 1ES","United Kingdom","UK",{"type":126,"coordinates":382},[383,384],-0.13947,50.82838,{"lat":384,"lon":383},[387],{"name":133,"role":113,"phone":388,"phoneExt":71,"email":71},"+44 01273 696 955",{"facility":390,"status":119,"city":391,"state":392,"zip":393,"country":379,"countryCode":380,"cosmosGeoPoint":394,"geoPoint":398,"contacts":399},"Royal Marsden Hospital ( Site 0402)","Fulham","England","SW3 6JJ",{"type":126,"coordinates":395},[396,397],-0.1993,51.48026,{"lat":397,"lon":396},[400],{"name":133,"role":113,"phone":401,"phoneExt":71,"email":71},"+442078118084",{"facility":403,"status":119,"city":404,"state":392,"zip":405,"country":379,"countryCode":380,"cosmosGeoPoint":406,"geoPoint":410,"contacts":411},"The Royal Marsden NHS Foundation Trust. ( Site 0403)","Sutton","SM2 5PT",{"type":126,"coordinates":407},[408,409],-0.2,51.35,{"lat":409,"lon":408},[412],{"name":133,"role":113,"phone":401,"phoneExt":71,"email":71},{"facility":414,"status":119,"city":415,"state":416,"zip":417,"country":379,"countryCode":380,"cosmosGeoPoint":418,"geoPoint":422,"contacts":423},"Barts Health NHS Trust ( Site 0401)","London","London, City of","E1 1RD",{"type":126,"coordinates":419},[420,421],-0.12574,51.50853,{"lat":421,"lon":420},[424],{"name":133,"role":113,"phone":425,"phoneExt":71,"email":71},"020 7377 7000",{"facility":427,"status":119,"city":428,"state":71,"zip":429,"country":379,"countryCode":380,"cosmosGeoPoint":430,"geoPoint":434,"contacts":435},"The Christie NHS Foundation Trust ( Site 0405)","Manchester","M20 4BX",{"type":126,"coordinates":431},[432,433],-2.23743,53.48095,{"lat":433,"lon":432},[436],{"name":133,"role":113,"phone":437,"phoneExt":71,"email":71},"+441619187689",{"type":439,"investigatorFullName":71,"investigatorTitle":71,"investigatorAffiliation":71,"oldNameTitle":71,"oldOrganization":71},"SPONSOR",[441],{"name":442,"class":6},"Daiichi Sankyo","100580910",false,"NCT06843447","A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","A Phase 1b\u002F2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy","Inclusion Criteria:\n\n* Has pathologically documented diagnosis of high-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer\n* Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1\n* Participants in Cohort A-1 Arms 2 and 3: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)\n* Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression \\\u003C6 months (\\\u003C180 days) after the last dose of platinum-based therapy (ie, platinum-resistant disease). Participants must have received no more than 1 prior bevacizumab-containing systemic treatment regimen\n* Participants in Cohort B-1 and Cohort B-2: Is a candidate for bevacizumab treatment\n* Has provided tumor tissue from a core or excisional biopsy of a tumor lesion not previously irradiated\n* Has an Eastern Cooperative Oncology Group performance status of 0 to 1 assessed within 7 days before allocation\u002Frandomization\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy\n* Participants who are hepatitis B surface antigen positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation\u002Frandomization\n* Participants with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening\n* Participants in Cohort C-1 and Cohort D: Has relapsed disease after 1 prior line of therapy, radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) and progressed during prior treatment with PARPi in the first-line setting\n* Cohort A-2 Arms 1, 2, and 3: Has relapsed disease after 1 prior line of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)\n\nExclusion Criteria:\n\n* Has any of the following within 6 months before allocation\u002Frandomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event\n* Has uncontrolled or significant cardiovascular disease\n* Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement, or prior pneumonectomy\n* Has ≥Grade 2 peripheral neuropathy\n* Has received prior treatment with cadherin-6-targeted agents\n* Has received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before allocation\n* Has received prior radiotherapy within 2 weeks of the start of study intervention, or has radiation-related toxicities, requiring corticosteroids\n* Receives chronic steroid treatment\n* Has known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has known active CNS metastases and\u002For carcinomatous meningitis\n* Has any history of interstitial lung disease (ILD)\u002Fpneumonitis irrespective of prior steroid use, current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening\n* Has active infection requiring systemic therapy\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease","FEMALE","18 Years",{"count":452,"type":453},460,"ESTIMATED","INTERVENTIONAL",[456,457],"PHASE1","PHASE2","Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes.\n\nStandard treatment (usual treatment) for people with relapsed high-grade serous ovarian cancer may include:\n\n* Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing\n* Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread\n\nRaludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.",[460],"Ovarian Cancer Recurrent","2026-06-24",{"date":463,"type":464},"2026-06-26","ACTUAL",{"date":466,"type":464},"2025-04-15",{"date":468,"type":453},"2029-03-27",{"name":5,"class":6},26]